Caroline serves as Global Head of Business Development at T-CURX with over 5 years of experience in Clinical Development and Business Development as well as 5 years in medical research. She supported Medtech and Biotech investments of the Impacting GmbH & Co KG, e.g. BioNTech SE at IPO (in 2019), GNA Biosolutions GmbH (since 2015), Dynamic Biosensors GmbH (since 2016), Araris Biotech AG (since 2020) and Semalytix GmbH (since 2021). Prior to joining T-CURX, she was Business Development Manager at Nuvisan Pharma Services Group, a CRO for pre-clinical and Phase I clinical developments. Whilst at Nuvisan she developed a strategy for CRO’s to partner with Venture Capital Companies. Prior to that, she was working in Business Development at Medpace, a CRO with focus on phase II and Phase III clinical developments, where she initially started in clinical trial management.

Caroline holds a PhD in Human Genetics from Technical University Munich, TUM, Germany, in collaboration with the Helmholtz Center Munich and the “Klinikum rechts der Isar”. During her PhD, she identified a new disease-causing gene by Next Generation Sequencing, developed a novel genetically modified mouse model, and tested a new therapeutic approach. Alongside her PhD studies she qualified as Clinical Research Associate. Prior to that, Caroline completed her Master studies in Genetics of Human Disease at University College London UCL, UK. During her thesis and during post-graduate studies at UCL she generated genome wide mutation libraries by DNA transposition, in order to find functional elements in the DNA.